Get Free Demat Account*
Open Your Free Demat Account
Enjoy low brokerage on delivery trades
By Dalal Street Investment Journal (DSIJ)
Zydus Lifesciences share price hit a 52-week high despite a weak market after the company reported strong Q4FY26 numbers, with revenue up 16.2% and EBITDA rising 20.2%. Investor sentiment was supported by margin expansion, adjusted profit growth, a 100% dividend recommendation and a ₹1,100 crore buyback at ₹1,150 per share, further lifting sentiment.
Zydus Lifesciences share price was in focus on May 20, with the stock trading higher by nearly 7% and hitting a fresh 52-week high, even as the broader market remained under pressure. Indian equities, meanwhile, were trading in the red, with Nifty 50 down 0.40% and Sensex down 0.44% at 9:45 a.m. IST.
Zydus Lifesciences reported revenue from operations of ₹7,587 crore in Q4FY26, compared with ₹6,527.9 crore in Q4FY25, reflecting a YoY growth of 16.2%. On a sequential basis, revenue rose 10.5% from ₹6,864.5 crore in Q3FY26.
EBITDA stood at ₹2,554.4 crore, up 20.2% from ₹2,125.5 crore in the same quarter last year. The EBITDA margin improved to 33.7% from 32.6% a year ago, marking an expansion of 110 basis points. Sequentially, EBITDA rose sharply by 40.6% from ₹1,816.4 crore.
Adjusted net profit for the quarter came in at ₹1,592.9 crore, against ₹1,390.5 crore in Q4FY25, showing a growth of 14.6%. Compared with Q3FY26, adjusted net profit increased 43.4% from ₹1,110.5 crore. The company has adjusted the numbers for exceptional items, including the one-time Mirabegron litigation settlement expense of ₹397.5 crore in Q4FY26.
Particulars | Q4FY26 ₹ in Crore | Q4FY25 ₹ in Crore | YoY Change in % | Q3FY26 ₹ in Crore | QoQ Change in % |
Revenue from Operations | 7,587 | 6,527.9 | 16.2% | 6,864.5 | 10.5% |
EBITDA | 2,554.4 | 2,125.5 | 20.2% | 1,816.4 | 40.6% |
EBITDA Margin | 33.7% | 32.6% | 110 bps | 26.5% | 720 bps |
Adjusted PBT | 2,057.2 | 1,891.6 | 8.8% | 1,438.3 | 43.0% |
Adjusted Net Profit | 1,592.9 | 1,390.5 | 14.6% | 1,110.5 | 43.4% |
For the full year FY26, Zydus Lifesciences reported revenue from operations of ₹27,148.4 crore, up 16.8% from ₹23,241.5 crore in FY25. EBITDA rose 20.1% to ₹8,475.1 crore from ₹7,058.5 crore. EBITDA margin improved to 31.2% from 30.4%, an expansion of 80 basis points.
Adjusted net profit for FY26 stood at ₹5,456.4 crore, compared with ₹4,745.1 crore in FY25, translating into a 15% YoY increase. Adjusted PBT rose 14.3% to ₹7,137.7 crore from ₹6,246.3 crore.
The pharma business remained the largest contributor, with Q4FY26 revenue of ₹5,643.6 crore, up 4.9% YoY. India Formulations delivered healthy growth, with revenue rising 14% to ₹1,752.8 crore. The company stated that its branded business grew faster than the market, while the chronic segment continued to support overall performance.
North America Formulations remained the biggest business within the pharma portfolio, but revenue declined 5.7% YoY to ₹2,952.3 crore. Sequentially, however, the business improved 5.3%. In constant currency terms, the business reported revenue of $323 million. During the quarter, Zydus filed 3 ANDAs, received approval for 9 ANDAs and launched 6 new products in the US generics market.
International Markets Formulations delivered one of the strongest performances, with revenue rising 45% YoY to ₹804.1 crore. The growth was broad-based across emerging markets and Europe. Consumer Wellness also posted a sharp jump, with Q4FY26 revenue rising 61.1% to ₹1,463.3 crore from ₹908.1 crore in Q4FY25.
Segment | Q4FY26 ₹ in Crore | Q4FY25 ₹ in Crore | YoY Change in % | Q3FY26 ₹ in Crore | QoQ Change in % |
Pharma Business | 5,643.6 | 5,380.4 | 4.9% | 5,523 | 2.2% |
India Formulations | 1,752.8 | 1,537.4 | 14.0% | 1,709.4 | 2.5% |
North America Formulations | 2,952.3 | 3,130.7 | -5.7% | 2,804.3 | 5.3% |
International Markets Formulations | 804.1 | 554.7 | 45.0% | 788.1 | 2.0% |
APIs | 121.9 | 129 | -5.5% | 214.3 | -43.1% |
Alliances and Others | 12.5 | 28.6 | -56.3% | 6.9 | 81.2% |
Consumer Wellness | 1,463.3 | 908.1 | 61.1% | 957.8 | 52.8% |
MedTech | 327.5 | 1.7 | Sharp rise on low base | 299.6 | 9.3% |
Zydus continued to invest in research and development. R&D investment for Q4FY26 stood at ₹698.2 crore, representing 9.2% of revenue. For FY26, R&D investment was ₹2,273.2 crore, or 8.4% of revenue. Organic capex stood at ₹357.7 crore for the quarter and ₹1,714.5 crore for the full year.
The company’s balance sheet remained comfortable, with net debt-to-equity at 0.16x and net debt-to-EBITDA at 0.50x as of March 31, 2026.
Zydus also reported progress across its innovation pipeline. Desidustat tablets, licensed to China Medical System Holdings in 2020, received approval from the Chinese regulator for renal anaemia. The USFDA granted Orphan Drug Designation to Desidustat for sickle cell disease. The company also received approval from DCGI to conduct two Phase III clinical trials in India for Zintrodiazine, its novel anti-malarial candidate.
On the inorganic growth front, Zydus signed a definitive agreement to acquire Assertio Holdings, a US-based pharmaceutical company focused on speciality and oncology supportive-care therapy, for $166 million. The acquisition is aimed at strengthening the company’s speciality presence in the US market.
The Board recommended a dividend of 100% for FY2025-26. It also approved a share buyback for an aggregate amount of up to ₹1,100 crore at ₹1,150 per share. The buyback price represents a 16% premium to the closing price on May 18, 2026. Based on the approved amount and buyback price, the offer works out to around 95.65 lakh shares.
Source: NSE, Dalal Street Investment Journal (DSIJ)
SEBI Registered Research Analyst (INH000006396).
Founded in 1986, Dalal Street Investment Journal (DSIJ) brings decades of experience in India’s equity markets. DSIJ's research combines fundamental analysis with price action, guided by disciplined risk management and capital preservation. They follow a structured, data-driven approach designed to help investors and traders make informed decisions beyond short-term market noise.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading